ABSTRACT
BACKROUND: In acute severe autoimmune hepatitis (AS-AIH), the early identification of predictors of non-response to corticosteroids and the optimal timing for liver transplantation (LT) remains controversial. AIMS: To determine early predictors of non-response to corticosteroids and to assess the usefulness of severity scores, namely the recently developed SURFASA. METHODS: Retrospective multicentre cohort study including consecutive patients admitted for AS-AIH between 2016 and 2020. Definitions- response to corticosteroids: LT-free survival at 90 days (D90); SURFASA score: -6.8 + 1.92x(D0-INR)+1.94xINR[(D3-D0)/D0]+1.64xbilirubin[(D3-D0)/D0]. RESULTS: We included 26 patients [median age 56 (45-69) years; 22 (84.6%) women]. All patients underwent corticosteroid therapy. Overall survival reached 73%. amongst the non-responders, 2 (7.8%) underwent LT and 5 (19.2%) died. The interval between admission and initiation of corticosteroids was not different between responders and non- responders [13 (7-23) vs. 8 (3-10), P:0.06], respectively. SURFASA and MELD-Na+ (D3) scores showed an AUROC of 0.96 (0.87-1) and 0.92 (0.82-0.99), respectively, for prediction of non-response. SURFASA >-2.5 had a sensitivity of 85.7% and a specificity of 100% and MELD-Na+ (D3) >26 had sensitivity of 85.7% and a specificity of 78% for the prediction of non-response. CONCLUSIONS: SURFASA and MELD-Na+ at D3 scores are useful in early identification of non-responders to corticosteroids.
Subject(s)
Hepatitis, Autoimmune , Liver Transplantation , Humans , Female , Middle Aged , Male , Hepatitis, Autoimmune/diagnosis , Hepatitis, Autoimmune/drug therapy , Liver Transplantation/adverse effects , Cohort Studies , Adrenal Cortex Hormones/therapeutic use , Acute DiseaseABSTRACT
We report a case of a man with chronic hepatitis C infection treated with remdesivir for COVID-19, resulting in lowered HCV viral load, followed by a rebound after its discontinuation. Concomitant treatment with tocilizumab possibly caused loss of anti-HBs.
ABSTRACT
BACKGROUND AND AIMS: Sorafenib, used for advanced-stage hepatocellular carcinoma (HCC), has an overall survival (OS) of 10 months. However, some patients have better response and long-term survival (LTS). Aims to assess predictive factors for LTS. METHODS: Retrospectively reviewed 77 advanced HCC patients, starting sorafenib treatment between 2007 and 2016, with LTS (OS ≥24 months) as primary endpoint. Univariate and multivariable analysis of clinical variables were performed in order to identify predictive factors for LTS. RESULTS: Patients: seventy (90.9%) males; median age: 65 years (39-82). All had cirrhosis mostly HCV infection (n = 32, 41.6%). Majority were Child-Pugh class A (n = 50, 64.9%); median MELD-Na: 11 (6-30). Multinodular HCC: 74% (n = 57); portal vein invasion (PVI): 50.6% (n = 39); extrahepatic spread: 18.2% (n = 14). Median time between HCC diagnosis and sorafenib start: 3.3 months (0-37.6). Median OS: 13 months [95% confidence interval (CI) 8.2-17.8]. Twenty-five (32.5%) patients were considered LTS, with amedian OS: 52.3 months (95% CI 17.1-87.4). Multivariable analysis identified Child-Pugh class A [odds ratio (OR) 11.1, 95% CI 1.78-69.54] and absence of PVI (OR 7.88, 95% CI 1.56-39.8) as independent predictors of LTS. Sub-analysis of Child-Pugh class A: absence of PVI (OR 7.13, 95% CI 1.69-30.2) and alpha-fetoprotein <400 ng/ml (OR 5.82, 95% CI 1.18-28.75) independently related to LTS. CONCLUSION: Despite global short median OS, sorafenib treatment is associated with longer than 2-year survival in a sub-group, more likely in compensated liver disease and absence of PVI.
Subject(s)
Antineoplastic Agents , Carcinoma, Hepatocellular , Liver Neoplasms , Aged , Antineoplastic Agents/adverse effects , Carcinoma, Hepatocellular/pathology , Humans , Liver Neoplasms/pathology , Male , Niacinamide/adverse effects , Phenylurea Compounds/adverse effects , Retrospective Studies , Sorafenib/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Telomeres are specialized DNA structures that are critical to maintain cell homeostasis and to avoid genomic instability. Epidemiological studies have examined the association between leukocyte telomere length (LTL) and risk of cancers, but the findings remain conflicting. METHODS: Mean LTL was measured by quantitative PCR in 97 patients with head and neck cancer (HNC) and 262 healthy controls. The association between LTL and patients' clinical status, such as smoke, alcoholism, and overall survival, were also evaluated. RESULTS: The age-adjusted LTL was significantly shorter in patients with HNC in comparison to healthy controls (P = .0003). Patients with shortest LTL had an increased risk to develop HNC (P < 0.0001). No significant correlation was observed between LTL and patients' clinical features and personal habits. CONCLUSIONS: Our data support the hypothesis that LTL is a risk factor for HNC. The use of LTL as a biomarker can help physicians to identify high-risk individuals for HNC.
Subject(s)
Head and Neck Neoplasms/pathology , Leukocytes/pathology , Telomere Shortening , Adult , Aged , Aged, 80 and over , Brazil , Case-Control Studies , Cohort Studies , Female , Head and Neck Neoplasms/mortality , Humans , Male , Middle Aged , Risk Factors , Survival Rate , Telomere HomeostasisABSTRACT
A 68-year-old female patient with Sjögren syndrome was admitted with asthenia, anorexia and weight loss. On the third day of admission, she developed severe hematemesis. Urgent upper gastrointestinal endoscopy (UGE) showed multiple gastric and duodenal ulcers, some with active bleeding requiring endoscopic therapy. The anatomopathologic examination was compatible with gastric and duodenal infiltration by a diffuse CD20+ large B cell lymphoma with germinal center B cell-like morphology. And the patient was referred for chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Although seldom observed, the risk of lymphoma in Sjögren syndrome is up to 44 times higher than the general population and rises 7 years after diagnosis. We present a brief case report with interesting iconography.
Subject(s)
Gastrointestinal Hemorrhage/complications , Sjogren's Syndrome/complications , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Endoscopy, Gastrointestinal , Fatal Outcome , Female , Gastrointestinal Hemorrhage/diagnostic imaging , Hematemesis/etiology , Humans , Sjogren's Syndrome/diagnostic imaging , Sjogren's Syndrome/drug therapyABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Sjogren's Syndrome/complications , Gastrointestinal Hemorrhage/etiology , Duodenal Neoplasms/surgery , Lymphoma, B-Cell/pathology , Neoplasm Metastasis/pathologyABSTRACT
A cura da forma cucosa de leishmaniose com antimonial pentavalente em esquema interrompido é apenas 56% parecendo-nos que o esquema aplicado sem interrupçäo seria mais eficaz. Achados de Chulay et al. parmitiram ao autor concluir que cardiotoxicidade dos antimoniais pentavalentes é diretamente proporcional à dosagem diária e tempo de uso, ocorrendo morte súbita com dose diária de 60mg SbV/Kg. Tratamos em torno de 300 casos com doses que variaram de 10 a 28mg SbV/Kg/dia com ambos tipos de esquema. Houve um caso de morte súbita e um caso de insuficiência renal aguda sem óbito. Nosso paciente tinha 77 anos e era portador de arritmia cardiáca. Tratado com dose de 20mg SbV/Kg?dia, morreu subitamente no 24§ dia. Admite-se que em pacientes idosos e com alteraçöes eletrocardiográficas prévias o uso de drogas menos cardiotóxicas (pentamidina e anfotericina B) deve ser considerado. O emprego de antimoniais nestes casos requer controle eletrocardiográfico cuidadoso
